Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer

20 Jan 2016

Abstract excerpt

Background The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice. Methods We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Colorectal Cancer Screening and Detection
Share to Digestive system and related health
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 26789870
DOI: 10.1056/nejmoa1506597

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon CancerPMID 26789870Read ↗

Quantitative analysis of CDX2 protein expression improves its clinical utility as a prognostic biomarker in stage II and III colon cancerSemantic proximity Read ↗

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.Semantic proximity Read ↗

Prognostic impact of CDX2 in stage II colon cancer: results from two nationwide cohortsSemantic proximity Read ↗

The prognostic potential of CDX2 in colorectal cancer: Harmonizing biology and clinical practiceSemantic proximity Read ↗

Combination of CDX2 expression and T stage improves prognostic prediction of colorectal cancerSemantic proximity Read ↗

Relationship of CDX2 Loss with Molecular Features and Prognosis in Colorectal CancerSemantic proximity Read ↗

Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.Semantic proximity Read ↗

CDX2 controls genes involved in the metabolism of 5-fluorouracil and is associated with reduced efficacy of chemotherapy in colorectal cancerSemantic proximity Read ↗

Cdx2 Controls Expression of the Protocadherin Mucdhl, an Inhibitor of Growth and β-Catenin Activity in Colon Cancer CellsSemantic proximity Read ↗

Machine Learning–Guided Differentiation Therapy Targets Cancer Stem Cells in Colorectal CancersSemantic proximity Read ↗

CDX2 Loss With Microsatellite Stable Phenotype Predicts Poor Clinical Outcome in Stage II Colorectal CarcinomaSemantic proximity Read ↗

SOX9 expression predicts relapse of stage II colon cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.